TP53 and acute myeloid leukemia: HDM201 combined with FLT3 (Fms-like tyrosine kinase 3) inhibitor can specifically induce apoptosis and death of FLT3-ITD positive TP53 wild-type AML cells [82], indicating that HDM201 has the potential to be combined with other targeted agents.